For cancer patients considering treatment options, understanding Molecular Tumor Board (MTB) benefits is essential. A major meta-analysis of 78 studies identifies three critical advantages: a 13% reduction in death risk, a 27% reduction in disease progression, and 75% higher treatment response rates compared to conventional approaches.
These findings have practical implications for oncology practice. MTBs bring together multidisciplinary experts to interpret each patient’s genetic profile and recommend tailored therapies, moving beyond one-size-fits-all treatment protocols. The evidence suggests that patients who access MTB-guided care experience measurable survival advantages and better disease control. For those facing cancer diagnosis, inquiring whether your treatment team utilizes molecular profiling and tumor board review may provide access to more personalized, effective therapeutic strategies backed by strong clinical evidence.
Read the full article on GMJ Newsroom.
Was this article helpful?
